Hybrid proteins of Cobra Venom Factor and cobra C3: Tools to identify functionally important regions in Cobra Venom Factor

Toxicon

Volumn 60, Issue 4, 2012, Pages 632-647

  Hew, Brian E ^a,d   Wehrhahn, Daniel ^c,e   Fritzinger, David C ^a   Vogel, Carl Wilhelm ^a,b,c  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

^d Black Ivory Biotech Inc   (United States)

^e Eppendorf Vertrieb Deutschland GmbH   (Germany)

Author keywords

C3 convertase; Cobra (Naja sp.); Cobra Venom Factor; Complement; Complement component C3; Hybrid proteins

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COBROTOXIN; COMPLEMENT COMPONENT C3; HYBRID PROTEIN;

ALPHA CHAIN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BETA CHAIN; CONTROLLED STUDY; GAMMA CHAIN; LOSS OF FUNCTION MUTATION; NAJA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; COBRA; COBRA VENOMS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT FACTOR D; ENZYME STABILITY; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

NAJA;

EID: 84863785107     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.05.004     Document Type: Article

References (60)

1. Alper C.A., Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 1976, 191:1275-1276.
2. Bammert H., Kunze B., Li Y., Fritzinger D.C., Bredehorst R., Vogel C.-W. Structure of the cobra venom factor (CVF) gene and comparison with the human C3 gene. Int. Immunopharmacol. 2002, 2:1275-1276.
3. Botto M. C3. The Complement Facts Book 2000, 87-94. Academic Press, New York. B.J. Morley, M.J. Walport (Eds.).
4. Cochrane C.G., Müller-Eberhard H.J., Aikin B.S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 1970, 105:55-69.
5. de Bruijn M.H., Fey G.H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:708-712.
6. DiScipio R.G., Smith C.A., Müller-Eberhard H.J., Hugli T.E. The activation of human complement component C5 by a fluid phase C5 convertase. J. Biol. Chem. 1983, 258:10629-10636.
7. Eggertsen G., Lind P., Sjöquist J. Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja n. siamensis). Mol. Immunol. 1981, 18:125-133.
8. Eggertsen G., Lundwall A., Hellman U., Sjöquist J. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja). J. Immunol. 1983, 131:1920-1923.
9. Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816-1820.
10. Fritzinger D.C., Petrella E.C., Connelly M.B., Bredehorst R., Vogel C.-W. Primary structure of cobra complement component C3. J. Immunol. 1992, 149:3554-3562.
11. Fritzinger D.C., Bredehorst R., Vogel C.-W. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. U.S.A 1994, 91:12775-12779.
12. Fritzinger D.C., Bredehorst R., Vogel C.-W. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7605. Correction.
13. Fritzinger D.C., Ferreira V.P., Hew B.E., St.John W., Pangburn M.K., Vogel C.-W. A novel concept for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): complement depletion with a human C3 derivative with cobra venom factor-like activity prevents lysis of PNH erythrocytes. Mol. Immunol. 2008, 45:4177.
14. Fritzinger D.C., Hew B.E., Lee J.Q., Newhouse J., Alam M., Ciallella J.R., Bowers M., Gorsuch W.B., Guikema B.J., Stahl G.L., Vogel C.-W. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv. Exp. Med. Biol. 2008, 632:293-307.
15. Fritzinger D.C., Hew B.E., Thorne M., Pangburn M.K., Janssen B.J., Gros P., Vogel C.-W. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev. Comp. Immunol. 2009, 33:105-116.
16. Fritzinger D.C., Dean R., Meschter C., Wong K., Halter R., Borlak J., St.John W.D., Vogel C.-W. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv. Exp. Med. Biol. 2010, 703:151-162.
17. Gorsuch W.B., Guikema B.J., Fritzinger D.C., Vogel C.-W., Stahl G.L. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol. Immunol. 2009, 47:506-510.
18. Götze O., Müller-Eberhard H.J. The C3-activator system: an alternate pathway of complement activation. J. Exp. Med. 1971, 134:90s-108s.
19. Grunwald T., Ziegelmüller P., Ollert M.W., Bredehorst R., Vogel C.-W. Cobra venom factor: an intact β-chain is not required for activity. Mol. Immunol. 1993, 30:13.
20. Grunwald T., Bredehorst R., Vogel C.-W. Cobra complement factor B: evidence for additional function as CVF-inhibitor. Mol. Immunol. 1996, 33:14.
21. Hensley P., O'Keefe M.C., Spangler C.J., Osborne J.C., Vogel C.-W. The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J. Biol. Chem. 1986, 261:11038-11044.
22. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989, 77:51-59.
23. Huda R., Fritzinger D.C., Finnegan P.F., Christadoss P., Vogel C.-W. Complement depletion with humanized cobra venom factor (CVF) improves the severity of experimental autoimmune myasthenia gravis (EAMG). Mol. Immunol. 2011, 48:1712.
24. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
25. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
26. Janssen B.J., Gomes L., Koning R.I., Svergun D.I., Koster A.J., Fritzinger D.C., Vogel C.-W., Gros P. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 2009, 28:2469-2478.
27. Kock M.A., Hew B.E., Bammert H., Fritzinger D.C., Vogel C.-W. Structure and function of recombinant cobra venom factor. J. Biol. Chem. 2004, 279:30836-30843.
28. Kölln J., Spillner E., Andrä J., Klensang K., Bredehorst R. Complement inactivation by recombinant human C3 derivatives. J. Immunol. 2004, 173:5540-5545.
29. Krishnan V., Ponnuraj K., Xu Y., Macon K., Volanakis J.E., Narayana S.V. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb. Structure 2009, 17:611-619.
30. Lachmann P.J., Halbwachs L. The influence of C3b inactivator (KAF) concentration on the abilityof serum to support complement activation. Clin. Exp. Immunol. 1975, 21:109-114.
31. Laursen N.S., Andersen K.R., Braren I., Spillner E., Sottrup-Jensen L., Andersen G.R. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 2011, 30:606-616.
32. Lesavre P.H., Hugli T.E., Esser A.F., Müller-Eberhard H.J. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 1979, 123:529-534.
33. Lundwall Å., Hellman U., Eggertsen G., Sjöquist J. Chemical characterization of cyanogen bromide fragments from the β-chain of human complement factor C3. FEBS Lett. 1984, 169:57-62.
34. Medicus R.G., Götze O., Müller-Eberhard H.J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 1976, 144:1076-1093.
35. Nagaki K., Iida K., Okubo M., Inai S. Reaction mechanisms of beta1H globulin. Int. Arch. Allergy Appl. Immunol. 1978, 57:221-232.
36. O'Keefe M.C., Caporale L.H., Vogel C.-W. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J. Biol. Chem. 1988, 263:12690-12697.
37. Pangburn M.K., Müller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 1986, 235:723-730.
38. Pangburn M.K., Schreiber R.D., Müller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J. Exp. Med. 1977, 146:257-269.
39. Petrella E.C., Wilkie S.D., Smith C.A., Morgan A.C., Vogel C.-W. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization. J. Immunol. Methods 1987, 104:159-172.
40. Pickering R.J., Wolfson M.R., Good R.A., Gewurz H. Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement. Proc. Natl. Acad. Sci. U.S.A. 1969, 62:521-527.
41. Rawal N., Pangburn M.K. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J. Biol. Chem. 1998, 273:16828-16835.
42. Rawal N., Pangburn M.K. Functional role of the noncatalytic subunit of complement C5 convertase. J. Immunol. 2000, 164:1379-1385.
43. Rawal N., Pangburn M.K. Structure/function of C5 convertases of complement. Int. Immunopharmacol 2001, 1:415-422.
44. Smith C.A., Vogel C.-W., Muller-Eberhard H.J. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement. J. Biol. Chem. 1982, 257:9879-9882.
45. Smith C.A., Vogel C.-W., Müller-Eberhard H.J. MHC Class III products: an electron microscopic study of the C3 convertases of human complement. J. Exp. Med. 1984, 159:324-329.
46. Takahashi K., Saha D., Shattino I., Pavlov V.I., Stahl G.L., Finnegan P., Melo M.F. Complement 3 is involved with ventilator-induced lung injury. Int. Immunopharmacol. 2011, 11:2138-2143.
47. Thai C.T., Ogata R.T. Expression and characterization of the C345C/NTR domains of complement components C3 and C5. J. Immunol. 2003, 171:6565-6573.
48. Vogel C.-W., Fritzinger D.C. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr. Pharm. Des. 2007, 13:2916-2926.
49. Vogel C.-W., Fritzinger D.C. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 2010, 56:1198-1222.
50. Vogel C.-W., Müller-Eberhard H.J. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J. Biol. Chem. 1982, 257:8292-8299.
51. Vogel C.-W., Müller-Eberhard H.J. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Methods 1984, 73:203-220.
52. Vogel C.-W., Smith C.A., Müller-Eberhard H.J. Cobra venom factor: structural homology with the third component of human complement. J. Immunol. 1984, 133:3235-3241.
53. Vogel C.-W., Bredehorst R., Fritzinger D.C., Grunwald T., Ziegelmüller P., Kock M.A. Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv. Exp. Med. Biol. 1996, 391:97-114.
54. Vogel C.-W., Fritzinger D.C., Hew B.E., Thorne M., Bammert H. Recombinant cobra venom factor. Mol. Immunol. 2004, 41:191-199.
55. Vogel C.-W. Cobra venom factor, the complement-activating protein of cobra venom. Handbook of Natural Toxins: Reptile and Amphibian Venoms 1991, vol. 5:p147-188. Marcel Dekker, New York.
56. Vogt W., Dieminger L., Lynen R., Schmidt G. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seyler's Z. Physiol. Chem. 1974, 355:171-183.
57. Vogt W., Schmidt G., von Buttlar B., Dieminger L. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 1978, 34:29-40.
58. von Zabern I., Hinsch B., Przyklenk H., Schmidt G., Vogt W. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 1980, 157:499-514.
59. Wang S.Y., Veeramani S., Racila E., Cagley J., Fritzinger D., Vogel C.-W., St John W., Weiner G.J. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
60. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta1H globulin. J. Exp. Med. 1976, 144:1147-1163.